Gbolahan OB - Search Results

1

Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.

Hashemi-Sadraei N, Gbolahan OB, Salfity H, O'Neil B, House MG, Shahda S. Hashemi-Sadraei N, et al. Among authors: gbolahan ob. Am J Clin Oncol. 2018 Oct;41(10):982-985. doi: 10.1097/COC.0000000000000409. Am J Clin Oncol. 2018. PMID: 28968257 Clinical Trial.

2

Locoregional and systemic therapy for hepatocellular carcinoma.

Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Gbolahan OB, et al. J Gastrointest Oncol. 2017 Apr;8(2):215-228. doi: 10.21037/jgo.2017.03.13. J Gastrointest Oncol. 2017. PMID: 28480062 Free PMC article. Review.

3

A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.

Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, Chiorean EG, Loehrer PJ Sr. Gbolahan OB, et al. J Thorac Oncol. 2018 Dec;13(12):1940-1948. doi: 10.1016/j.jtho.2018.07.094. Epub 2018 Aug 16. J Thorac Oncol. 2018. PMID: 30121390 Free article. Clinical Trial.

4

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.

Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH. Sehdev A, et al. Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131383 Free article.

5

Update on systemic therapy for colorectal cancer: biologics take sides.

Gbolahan O, O'Neil B. Gbolahan O, et al. Transl Gastroenterol Hepatol. 2019 Feb 13;4:9. doi: 10.21037/tgh.2019.01.12. eCollection 2019. Transl Gastroenterol Hepatol. 2019. PMID: 30976712 Free PMC article. Review.

6

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.

Gbolahan OB, Tong Y, Sehdev A, O'Neil B, Shahda S. Gbolahan OB, et al. BMC Cancer. 2019 May 17;19(1):468. doi: 10.1186/s12885-019-5630-4. BMC Cancer. 2019. PMID: 31101022 Free PMC article.

7

Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.

Gbolahan O, Hashemi-Sadraei N, O'Neil B. Gbolahan O, et al. J Natl Compr Canc Netw. 2019 Jun 1;17(6):644-648. doi: 10.6004/jnccn.2019.7304. J Natl Compr Canc Netw. 2019. PMID: 31200359

8

A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors.

Gbolahan OB, O'Neil BH, McRee AJ, Sanoff HK, Fallon JK, Smith PC, Ivanova A, Moore DT, Dumond J, Asher GN. Gbolahan OB, et al. Clin Transl Sci. 2022 May;15(5):1304-1315. doi: 10.1111/cts.13250. Epub 2022 Feb 26. Clin Transl Sci. 2022. PMID: 35157783 Free PMC article. Clinical Trial.

9

The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy.

Irfan A, Rose JB, Wang TN, Vickers SM, Dudeja V, Gbolahan O, Reddy S. Irfan A, et al. Pancreas. 2022 Jan 1;51(1):100-105. doi: 10.1097/MPA.0000000000001972. Pancreas. 2022. PMID: 35195602

10

Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?

Irfan A, Fang HA, Awad S, Alkashah A, Vickers SM, Gbolahan O, Williams GR, Nien-Tsu Wang T, Dudeja V, Rose JB, Reddy S. Irfan A, et al. Am J Surg. 2022 Sep;224(3):955-958. doi: 10.1016/j.amjsurg.2022.04.004. Epub 2022 Apr 12. Am J Surg. 2022. PMID: 35430088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters